Phase 4 N=30 Human Fibrinogen Concentrate in Pediatric Cardiac Surgery
Hypofibrinogenemia · Afibrinogenemia · Bleeding Disorders
Primary: Postoperative Blood Loss After Surgery (Estimated Blood Loss (EBL)) — 35; 33 cc/kg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=80 Pilot Study of the Safety and Efficacy of Four Different Potencies of Smoked Marijuana in 76 Veterans With PTSD
Posttraumatic Stress Disorder
Primary: Baseline CAPS-5 Total Severity Score — 36.6; 36.8; 38.0; 37.3 score on a scale
Phase 2 N=32 Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Refractory Plasma Cell Myeloma · Recurrent Plasma Cell Myeloma
Primary: Number of Patients With Dose-Limiting Toxicities (Phase I) — 1; 1 Participants
Phase 2 N=36 Lentiviral (LV) Gene Therapy for Adenosine Deaminase (ADA) Deficiency
Adenosine Deaminase Deficiency · Severe Combined Immunodeficiencies (SCID)
Primary: Overall Survival (OS) of Subjects Treated With Investigational Medicinal Product (IMP) (1 Year) — 100; 100; 100; 100 percentage of participants
Phase 2 N=55 Cabozantinib for Adults With Advanced Soft Tissue Sarcoma
Refractory Soft Tissue Sarcomas
Primary: Objective Response (Complete Response (CR)+Partial Response (PR) of Cabozantinib in Patients With Soft Tissue Sarcomas — 11.1 percentage of particpants
N/A N=66 Evaluation of the Performance of Different Daily Disposable Lens Designs in Habitual Soft Contact Lens Wearers
Myopia
Primary: Lens Wettability — 3.7; 3.7 units on a scale
N/A N=571 Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers
SARS-CoV-2
Primary: Number of Participant Health Care Workers With a Positive Rapid, At-home, Point-of-care (POC) SARS-CoV2 IgG Antibody Test. — 8 Participants
N/A N=1,417 Spanish-Language Smoking Cessation Trial
Smoking Cessation
Primary: Percentage of Participants With Tobacco Abstinence at 6 Months — 21.7; 11.3 percentage of participants
Phase 3 N=44 Antibacterial Effect of Nano Silver Fluoride vs Chlorhexidine on Occlusal Carious Molars Treated With Partial Caries Removal Technique
Dental Caries
Primary: Bacterial Count of Streptococus Mutans — 2.00; 2.04; 1.12; 1.05 CFU/ml log10
Phase 2 N=70 Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Ocular Itching — 0.508; 0.139; 2.485; 2.535 score on a scale — p=0.0882
Phase 2 N=132 A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis
Non-Alcoholic Steatohepatitis
Primary: Mean Change From Baseline (Average) in Alanine Aminotransferase (ALT) at Week 12 — -13.85; -23.76; -26.14 units per liter (U/L) — p=0.0495
Phase 2 N=44 Steroid Dosing by bioMARker Guided Titration in Critically Ill Patients With Pneumonia
Pneumonia
Primary: Timely Initiation of Corticosteroids and Implementation of Biomarker-titrated Corticosteroid Dosing — 20; 19 Participants
Phase 3 N=204 Adjuvant HIPEC in High Risk Colon Cancer
Colorectal Neoplasms · Peritoneal Neoplasms
Primary: Peritoneal Recurrence Free Survival at 18 Months — 79; 80 participants
Phase 2 N=34 CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease
Melanoma · Lymph Node Cancer
Primary: Major Pathologic Response Rate (MPR) — 14; 3; 3; 10 Participants
N/A N=120 Monitoring Movement and Health Study
Pregnancy Related · Obesity · Hypertension
Primary: Number of Participants Classified as Having High Sedentary Behavior (by Trajectory) — 45 Participants